KR20190065382A - TCRα 호밍 엔도뉴클레아제 변이체 - Google Patents

TCRα 호밍 엔도뉴클레아제 변이체 Download PDF

Info

Publication number
KR20190065382A
KR20190065382A KR1020197013234A KR20197013234A KR20190065382A KR 20190065382 A KR20190065382 A KR 20190065382A KR 1020197013234 A KR1020197013234 A KR 1020197013234A KR 20197013234 A KR20197013234 A KR 20197013234A KR 20190065382 A KR20190065382 A KR 20190065382A
Authority
KR
South Korea
Prior art keywords
leu
lys
gly
val
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020197013234A
Other languages
English (en)
Korean (ko)
Inventor
조던 자르주르
마크 포그슨
Original Assignee
블루버드 바이오, 인코포레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 블루버드 바이오, 인코포레이티드. filed Critical 블루버드 바이오, 인코포레이티드.
Publication of KR20190065382A publication Critical patent/KR20190065382A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/11—Exodeoxyribonucleases producing 5'-phosphomonoesters (3.1.11)
    • C12Y301/11002—Exodeoxyribonuclease III (3.1.11.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Television Signal Processing For Recording (AREA)
  • Peptides Or Proteins (AREA)
  • Treating Waste Gases (AREA)
KR1020197013234A 2016-10-11 2017-10-11 TCRα 호밍 엔도뉴클레아제 변이체 Withdrawn KR20190065382A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662406689P 2016-10-11 2016-10-11
US62/406,689 2016-10-11
US201662414266P 2016-10-28 2016-10-28
US62/414,266 2016-10-28
PCT/US2017/056178 WO2018071565A1 (en) 2016-10-11 2017-10-11 TCRa HOMING ENDONUCLEASE VARIANTS

Publications (1)

Publication Number Publication Date
KR20190065382A true KR20190065382A (ko) 2019-06-11

Family

ID=61905974

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197013234A Withdrawn KR20190065382A (ko) 2016-10-11 2017-10-11 TCRα 호밍 엔도뉴클레아제 변이체

Country Status (13)

Country Link
US (2) US11591582B2 (https=)
EP (1) EP3534916A4 (https=)
JP (1) JP7104710B2 (https=)
KR (1) KR20190065382A (https=)
CN (1) CN110036107B (https=)
AU (1) AU2017342273B2 (https=)
CA (1) CA3039812A1 (https=)
IL (1) IL265895A (https=)
MA (1) MA46717A (https=)
MX (1) MX2019004156A (https=)
RU (1) RU2019114035A (https=)
SG (1) SG11201903230QA (https=)
WO (1) WO2018071565A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
KR102451510B1 (ko) 2016-09-08 2022-10-07 2세븐티 바이오, 인코포레이티드 Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법
US11591582B2 (en) 2016-10-11 2023-02-28 2Seventy Bio, Inc. TCRα homing endonuclease variants
MA46543A (fr) 2016-10-17 2019-08-21 Bluebird Bio Inc Variants de l'endonucléase tgfbéta r2, compositions et procédés d'utilisation
JP2022513750A (ja) 2018-12-10 2022-02-09 ２セブンティ バイオ インコーポレイテッド ホーミングエンドヌクレアーゼバリアント
IL283724B1 (en) 2018-12-10 2026-02-01 Genetix Biotherapeutics Inc pdcd-1 homing endonuclease variants
JP2024503249A (ja) * 2020-12-21 2024-01-25 ２セブンティ バイオ インコーポレイテッド 部位特異的変異導入のための組成物及び方法
US20240218351A1 (en) 2021-06-14 2024-07-04 2Seventy Bio, Inc. Single stranded rna purification methods
CA3237482A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
ES2061416T3 (es) 1990-10-12 1997-03-01 Max Planck Gesellschaft Ribozimas modificadas.
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US20020119158A1 (en) * 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
IL160359A0 (en) * 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
KR100415267B1 (ko) * 2002-02-19 2004-01-16 오광수 2단 발효법에 의한 고 순도 멸치액젓 및 그 제조방법
EP1413626A1 (en) * 2002-10-23 2004-04-28 Vicuron Pharmaceuticals, Inc. Genes and proteins for the biosynthesis of the glycopeptide antibiotic A40926
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US20140148361A1 (en) 2010-06-07 2014-05-29 Barry L. Stoddard Generation and Expression of Engineered I-ONUI Endonuclease and Its Homologues and Uses Thereof
US9034813B2 (en) * 2010-09-17 2015-05-19 Ecolab Usa Inc. High performance low viscoelasticity foaming detergent compositions employing extended chain anionic surfactants
BR112013030652A2 (pt) * 2011-06-10 2016-12-13 Basf Plant Science Co Gmbh polinucleotídeo que codifica um polipeptídeo, molécula de ácido nucleico, vetor, organismo não humano, polipeptídeo e método para introduzir um ácido nucleico de interesse em um genoma de um organismo não humano
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
BR112014029417B1 (pt) 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
ES2716867T3 (es) * 2013-05-31 2019-06-17 Cellectis Sa Endonucleasa de asentamiento LAGLIDADG que escinde el gen de receptor de células T alfa y usos de la misma
US11591582B2 (en) 2016-10-11 2023-02-28 2Seventy Bio, Inc. TCRα homing endonuclease variants

Also Published As

Publication number Publication date
SG11201903230QA (en) 2019-05-30
AU2017342273A1 (en) 2019-05-09
MX2019004156A (es) 2019-09-26
CA3039812A1 (en) 2018-04-19
CN110036107A (zh) 2019-07-19
US20230357736A1 (en) 2023-11-09
EP3534916A4 (en) 2020-09-30
RU2019114035A (ru) 2020-11-13
US12264343B2 (en) 2025-04-01
JP2019532674A (ja) 2019-11-14
US20220186198A1 (en) 2022-06-16
WO2018071565A1 (en) 2018-04-19
US11591582B2 (en) 2023-02-28
CN110036107B (zh) 2024-12-27
IL265895A (en) 2019-06-30
EP3534916A1 (en) 2019-09-11
JP7104710B2 (ja) 2022-07-21
AU2017342273B2 (en) 2023-07-06
MA46717A (fr) 2019-09-11

Similar Documents

Publication Publication Date Title
US12264343B2 (en) TCRa homing endonuclease variants
EP3847189B1 (en) Universal donor cells
JP6965466B2 (ja) 操作されたカスケード構成要素およびカスケード複合体
ES2952525T3 (es) Variantes de endonucleasa homing PD-1, composiciones y métodos de uso
ES2969213T3 (es) Plantillas de reparación de donantes para edición multiplex del genoma
CA3062506A1 (en) Materials and methods for engineering cells and uses thereof in immuno-oncology
JP7060591B2 (ja) ＴＧＦβＲ２エンドヌクレアーゼバリアント、組成物、および使用方法
WO2018035141A1 (en) Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use
JP2019525759A (ja) Ｂｃｌ１１ａホーミングエンドヌクレアーゼバリアント、組成物、および使用方法
JP2024109943A (ja) ブルトン型チロシンキナーゼに対するｔａｌｅｎベースのおよびｃｒｉｓｐｒ／ｃａｓベースのゲノム編集
WO2019126558A1 (en) Ahr homing endonuclease variants, compositions, and methods of use
JP2025072470A (ja) ホーミングエンドヌクレアーゼバリアント
US20220364123A1 (en) Wiskott-aldrich syndrome gene homing endonuclease variants, compositions, and methods of use
US20210230565A1 (en) Bruton's tyrosine kinase homing endonuclease variants, compositions, and methods of use
HK40114886A (en) Universal donor cells
JP2024503249A (ja) 部位特異的変異導入のための組成物及び方法
HK40058224B (en) Universal donor cells
HK40058224A (en) Universal donor cells

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000